Canada markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
55.05-1.11 (-1.98%)
At close: 04:00PM EDT
54.54 -0.51 (-0.93%)
After hours: 06:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close56.16
Open56.16
Bid55.03 x 100
Ask55.08 x 400
Day's Range54.28 - 57.49
52 Week Range37.55 - 91.10
Volume1,761,377
Avg. Volume1,780,425
Market Cap4.673B
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

    ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the

  • GlobeNewswire

    CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

    ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucom

  • GlobeNewswire

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year. “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Boar